Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer
Overview
This is an open label, non-interventional quality of life analysis for Arimidex treated postmenopausal patients in early breast cancer by investigator's questionnaire
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: July 2010
Clinical Trial Outcome Measures
Primary Measures
- Elements of the investigator questionnaire SF RAND-36 questionnaire
- Time Frame: Quarterly (plus or minus 3 days )
Secondary Measures
- Investigator Assessment Report
- Time Frame: Yearly (plus or minus 1 week )
Participating in This Clinical Trial
Inclusion Criteria
- Provision of informed consent – Postmenopausal, hormon receptor positive patients with early breast cancer treated with Arimidex – Investigators are requested to recruit patients only with at least 1 month prior Arimidex treatment. Exclusion Criteria:
- Allergy to substance of medication – Pre-perimenopausal woman – Woman not eligible for treatment
Gender Eligibility: Female
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- AstraZeneca
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Zsolt Horváth, M.D., Principal Investigator, National Institute of Oncology
- Csaba Csongvai, Study Director, AstraZeneca Hungary
- Éva Gulyás, Study Chair, AstraZeneca Hungary
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.